GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » YoY Rev. per Sh. Growth

ValiRx (LSE:VAL) YoY Rev. per Sh. Growth : 0.00% (As of Dec. 2024)


View and export this data going back to 2000. Start your Free Trial

What is ValiRx YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. ValiRx's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2024 was 0.00%.

ValiRx's Revenue per Share for the six months ended in Dec. 2024 was £0.00.

ValiRx YoY Rev. per Sh. Growth Historical Data

The historical data trend for ValiRx's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx YoY Rev. per Sh. Growth Chart

ValiRx Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ValiRx Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ValiRx YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

ValiRx's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2024 )
=(Revenue per Share (A: Dec. 2024 )-Revenue per Share (A: Dec. 2023 ))/ | Revenue per Share (A: Dec. 2023 ) |
=(0-0)/ | 0 |
=N/A %

ValiRx's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY Rev. per Sh. Growth (Q: Dec. 2024 )
=(Revenue per Share (Q: Dec. 2024 )-Revenue per Share (Q: Dec. 2023 )) / | Revenue per Share (Q: Dec. 2023 )) |
=(0-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ValiRx YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of ValiRx's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

ValiRx Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » YoY Rev. per Sh. Growth
Comparable Companies
LSE:BSFA LSE:ROQ LSE:NFX LSE:PYC LSE:GENF LSE:TCF LSE:CRTX AQSE:INC LSE:FAB LSE:HEMO VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
D6 Thane Road, MediCity Nottingham, Nottingham, GBR, NG90 6BH
Website
https://www.valirx.com
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.